Please login to the form below

Not currently logged in
Email:
Password:

Report reveals best-in-class, cross-functional marketing teams

A new Best Practices report reveals how an effective cross-functional team can lay the groundwork for a new pharmaceutical product's success in the marketplace, both initially and long-term.

A new Best Practices report reveals how an effective cross-functional team can lay the groundwork for a new pharmaceutical product's success in the marketplace, both initially and long-term.

Pharma companies say that the various activities of a cross-functional team are responsible for half of a drug's success, with the other half embedded in the biological attributes of the compound, according to Best Practices, a US-based research and consultancy company.

The report, entitled "Managing Cross-Functional Teams for Pharmaceutical Product Commercialisation Excellence", reveals the best-in-class practices implemented by leading companies use to establish effective cross-functional teams, such as empowering teams to make key decisions and make teams follow standardised processes.

In the study, companies found benefit in moving various marketing activities up in the development schedule to help understand market needs earlier in the process. A sample of study participants found that teams averaged 0.5 marketing FTEs at pre-clinical, 1.8 marketing FTEs at phase II and 5.6 marketing FTEs at launch.

Study participants included Amgen, Novartis, GlaxoSmithKline, Merck and Johnson & Johnson. Findings were based on a two-pronged research approach:
benchmark surveys were performed on more than 49 companies and interviews with directors and managers involved with managing teams across units, functions or countries.


28th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics